Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00486
|
|||||
| Drug Name |
Protriptyline
|
|||||
| Synonyms |
3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene; Amimetilina; Apo-Imipramine; Apo-Trimip; Impril; Maximed; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; Normethyl EX4442; Novo-Doxepin; Novo-Tripramine; Novopramine; Protriptilina; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum; Protriptylinum [INN-Latin]; Protryptyline; Rhotrimine; Triadapin 5; Triptil; Triptil hydrochloride; Triptyl; Vivactil; Vivactil (TN); Vivactyl
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Depression [ICD11: 6A8Z] | Approved | [1] | |||
| Therapeutic Class |
Antidepressants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H21N
|
|||||
| Canonical SMILES |
CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13
|
|||||
| InChI |
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
|
|||||
| InChIKey |
BWPIARFWQZKAIA-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 438-60-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 263.4 | Topological Polar Surface Area | 12 | ||
| Heavy Atom Count | 20 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
4.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103189728
, 104061736
, 104307929
, 10522905
, 11111679
, 11111680
, 11466958
, 11468078
, 11486755
, 124750138
, 124881218
, 124881219
, 124881220
, 126623989
, 127578602
, 134338142
, 134974679
, 137001421
, 142365103
, 15221639
, 29214865
, 29224052
, 46505128
, 47291296
, 47365392
, 47589161
, 47736675
, 47736676
, 47959952
, 48035323
, 48416494
, 4903494
, 49699033
, 49961823
, 50100330
, 50104299
, 57322553
, 78122381
, 7849630
, 794681
, 7980423
, 8153064
, 85177328
, 85209617
, 85787376
, 90341254
, 92714631
, 93167175
, 96025133
, 9612
|
|||||
| ChEBI ID |
ChEBI:8597
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Protriptyline was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.